FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309609404> ?p ?o ?g. }

• W4309609404 abstract "Introduction Cluster seizures (CS) and status epilepticus (SE) in dogs are severe neurological emergencies that require immediate treatment. Practical guidelines call for constant rate infusion (CRI) of benzodiazepines or propofol (PPF) in patients with seizures not responding to first-line treatment, but to date only few studies have investigated the use of CRI in dogs with epilepsy. Study design Retrospective clinical study. Methods Dogs that received CRI of diazepam (DZP) or PPF for antiepileptic treatment during hospitalization at the Veterinary Teaching Hospital of the University of Turin for CS or SE between September 2016 and December 2019 were eligible for inclusion. Favorable outcome was defined as cessation of clinically visible seizure activity within few minutes from the initiation of the CRI, no seizure recurrence within 24 h after discontinuation of CRI through to hospital discharge, and clinical recovery. Poor outcome was defined as recurrence of seizure activity despite treatment or death in hospital because of recurrent seizures, catastrophic consequences of prolonged seizures or no return to an acceptable neurological and clinical baseline, despite apparent control of seizure activity. Comparisons between the number of patients with favorable outcome and those with poor outcome in relation to type of CRI, seizure etiology, reason for presentation (CS or SE), sex, previous AED therapy and dose of PPF CRI were carried out. Results A total of 37 dogs, with 50 instances of hospitalization and CRI administered for CS or SE were included in the study. CRI of diazepam (DZP) or PPF was administered in 29/50 (58%) and in 21/50 (42%) instances of hospitalization, respectively. Idiopathic epilepsy was diagnosed in 21/37 (57%), (13/21 tier I and 8/21 tier II); structural epilepsy was diagnosed in 6/37 (16%) of which 4/6 confirmed and 2/6 suspected. A metabolic or toxic cause of seizure activity was recorded in 7/37 (19%). A total of 38/50 (76%) hospitalizations were noted for CS and 12/50 (24%) for SE. In 30/50 (60%) instances of hospitalization, the patient responded well to CRI with cessation of seizure activity, no recurrence in the 24 h after discontinuation of CRI through to hospital discharge, whereas a poor outcome was recorded for 20/50 (40%) cases (DZP CRI in 12/50 and PPF CRI in 8/50). Comparison between the number of patients with favorable outcome and those with poor outcome in relation to type of CRI, seizure etiology, reason for presentation (CS or SE), sex and previous AED therapy was carried out but no statistically significant differences were found. Conclusions The present study is the first to document administration of CRI of DZP or PPF in a large sample of dogs with epilepsy. The medications appeared to be tolerated without major side effects and helped control seizure activity in most patients regardless of seizure etiology. Further studies are needed to evaluate the effects of CRI duration on outcome and complications." @default.
• W4309609404 created "2022-11-28" @default.
• W4309609404 creator A5006151206 @default.
• W4309609404 creator A5022015613 @default.
• W4309609404 creator A5046422215 @default.
• W4309609404 creator A5060425190 @default.
• W4309609404 creator A5063301639 @default.
• W4309609404 creator A5071444182 @default.
• W4309609404 creator A5073079389 @default.
• W4309609404 creator A5083094334 @default.
• W4309609404 creator A5089920265 @default.
• W4309609404 date "2022-11-17" @default.
• W4309609404 modified "2023-10-12" @default.
• W4309609404 title "Constant rate infusion of diazepam or propofol for the management of canine cluster seizures or status epilepticus" @default.
• W4309609404 cites W1511457711 @default.
• W4309609404 cites W1539321373 @default.
• W4309609404 cites W1556008197 @default.
• W4309609404 cites W1565364436 @default.
• W4309609404 cites W1846322569 @default.
• W4309609404 cites W1905138928 @default.
• W4309609404 cites W1912713749 @default.
• W4309609404 cites W1941551863 @default.
• W4309609404 cites W1965035617 @default.
• W4309609404 cites W1978022925 @default.
• W4309609404 cites W1988774842 @default.
• W4309609404 cites W1992335123 @default.
• W4309609404 cites W2000899854 @default.
• W4309609404 cites W2025002374 @default.
• W4309609404 cites W2029569324 @default.
• W4309609404 cites W2044906358 @default.
• W4309609404 cites W2058541251 @default.
• W4309609404 cites W2063899003 @default.
• W4309609404 cites W2071542329 @default.
• W4309609404 cites W2073069032 @default.
• W4309609404 cites W2074265790 @default.
• W4309609404 cites W2098012622 @default.
• W4309609404 cites W2104047366 @default.
• W4309609404 cites W2136184555 @default.
• W4309609404 cites W2165926195 @default.
• W4309609404 cites W2205029600 @default.
• W4309609404 cites W2220161319 @default.
• W4309609404 cites W2252496421 @default.
• W4309609404 cites W2281144116 @default.
• W4309609404 cites W2507902224 @default.
• W4309609404 cites W2523056128 @default.
• W4309609404 cites W2558627353 @default.
• W4309609404 cites W2608435941 @default.
• W4309609404 cites W2609553079 @default.
• W4309609404 cites W2620467160 @default.
• W4309609404 cites W2938118100 @default.
• W4309609404 cites W3081330990 @default.
• W4309609404 cites W3091986623 @default.
• W4309609404 cites W3111014323 @default.
• W4309609404 cites W3130109397 @default.
• W4309609404 cites W3133877015 @default.
• W4309609404 cites W4207081546 @default.
• W4309609404 doi "https://doi.org/10.3389/fvets.2022.1005948" @default.
• W4309609404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36467660" @default.
• W4309609404 hasPublicationYear "2022" @default.
• W4309609404 type Work @default.
• W4309609404 citedByCount "1" @default.
• W4309609404 countsByYear W43096094042023 @default.
• W4309609404 crossrefType "journal-article" @default.
• W4309609404 hasAuthorship W4309609404A5006151206 @default.
• W4309609404 hasAuthorship W4309609404A5022015613 @default.
• W4309609404 hasAuthorship W4309609404A5046422215 @default.
• W4309609404 hasAuthorship W4309609404A5060425190 @default.
• W4309609404 hasAuthorship W4309609404A5063301639 @default.
• W4309609404 hasAuthorship W4309609404A5071444182 @default.
• W4309609404 hasAuthorship W4309609404A5073079389 @default.
• W4309609404 hasAuthorship W4309609404A5083094334 @default.
• W4309609404 hasAuthorship W4309609404A5089920265 @default.
• W4309609404 hasBestOaLocation W43096094041 @default.
• W4309609404 hasConcept C118552586 @default.
• W4309609404 hasConcept C126322002 @default.
• W4309609404 hasConcept C137627325 @default.
• W4309609404 hasConcept C187212893 @default.
• W4309609404 hasConcept C2776175493 @default.
• W4309609404 hasConcept C2776277131 @default.
• W4309609404 hasConcept C2777341932 @default.
• W4309609404 hasConcept C2778186239 @default.
• W4309609404 hasConcept C2778715236 @default.
• W4309609404 hasConcept C42219234 @default.
• W4309609404 hasConcept C71924100 @default.
• W4309609404 hasConceptScore W4309609404C118552586 @default.
• W4309609404 hasConceptScore W4309609404C126322002 @default.
• W4309609404 hasConceptScore W4309609404C137627325 @default.
• W4309609404 hasConceptScore W4309609404C187212893 @default.
• W4309609404 hasConceptScore W4309609404C2776175493 @default.
• W4309609404 hasConceptScore W4309609404C2776277131 @default.
• W4309609404 hasConceptScore W4309609404C2777341932 @default.
• W4309609404 hasConceptScore W4309609404C2778186239 @default.
• W4309609404 hasConceptScore W4309609404C2778715236 @default.
• W4309609404 hasConceptScore W4309609404C42219234 @default.
• W4309609404 hasConceptScore W4309609404C71924100 @default.
• W4309609404 hasLocation W43096094041 @default.
• W4309609404 hasLocation W43096094042 @default.
• W4309609404 hasLocation W43096094043 @default.
• W4309609404 hasLocation W43096094044 @default.
• W4309609404 hasOpenAccess W4309609404 @default.

• next